We are a UK medtech company focused on developing novel biosensors for use in Point-of-Care in-vitro diagnostic (PoC IVD) applications where there is a clear unmet need for improved patient healthcare and cost reduction.
Our patented technology delivers a step change in sensitivity and selectivity enabling new biomarkers to be measured within minutes in finger-prick samples of unprocessed whole blood. These sensors are low cost, single-use biosensors with a portable handheld reader creating new point-of-care diagnostics not previously possible.
Our initial focus is purines, the earliest detectable biomarkers of cell/tissue hypoxia and ischaemia. Changes to blood purine levels occur because of acute injuries such as stroke, traumatic brain injury (TBI), heart attacks, foetal hypoxia and limb ischaemia. Purine levels provide a valuable clinical insight into underlying pathology and prognosis, and can be used – from the earliest point of injury – in decisions regarding the administration of a timely course of treatment, and in the monitoring of treatment outcomes.
Bill is a US-based industry veteran with over 35 years’ experience of building early stage medtech companies into $100m plus businesses. Bill was the CEO and President of i-Stat, a PoC diagnostic company he built and sold to Abbott for $480m in 2004.
Everard is an experienced commercial manager with some 25yrs plus of commercialising earlystage technology. He has built 2 start-ups from concept through to revenues and secured several £m of
investment for these companies. He is responsible for the commercial operations of the company. Prior to joining Sarissa, Everard was an Investment Executive with Mercia Fund Management, he is also an NXD on 3 other early stage technology companies.
Nick is the founder of Sarissa Biomedical and Ted Pridgeon Professor of Neuroscience. His expertise is in the fields of neuroscience and biosensors and has received over £9m of grantfunding from UK research councils, medical charities and the EU and is the co-inventor on 5 patents and has published more than 100 peer-reviewed papers in international scientific journals. Nick directs the technical work of the company and is the Principal Investigator on the clinical trials.
Faming is an expert in electrochemistry and sensor technology.Together with Nick, Faming has been responsible for many of the key technical developments. Faming is responsible for the development of the company’s biosensor technologies and production facilities.